This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids
by Zacks Equity Research
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold
by Zacks Equity Research
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
Kamada (KMDA) Q1 Earnings Top Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Kamada (KMDA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Consider Kamada (KMDA) Stock Now?
by Zacks Equity Research
Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.
Kamada (KMDA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Kamada (KMDA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS
3 Plasma Stocks to Win Big on FDA's Convalescent EUA
by Tirthankar Chakraborty
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Kamada (KMDA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kamada (KMDA) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
How Kamada (KMDA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kamada (KMDA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
by Zacks Equity Research
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
Weekly Biotech Update After WHO Declares Coronavirus a Pandemic
by Zacks Equity Research
Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
Why Kamada (KMDA) Could Beat Earnings Estimates Again
by Zacks Equity Research
Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Kamada (KMDA) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 66.67% and 14.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 6.67% and 4.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.